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Purpose: Magnetic resonance imaging (MRI) is increasingly used for radiotherapy target delineation,
image guidance, and treatment response monitoring. Recent studies have shown that an entire external
x-ray radiotherapy treatment planning (RTP) workflow for brain tumor or prostate cancer patients
based only on MRI reference images is feasible. This study aims to show that a MRI-only based RTP
workflow is also feasible for proton beam therapy plans generated in MRI-based substitute computed
tomography (sCT) images of the head and the pelvis.
Methods: The sCTs were constructed for ten prostate cancer and ten brain tumor patients primarily by
transforming the intensity values of in-phase MR images to Hounsfield units (HUs) with a dual model
HU conversion technique to enable heterogeneous tissue representation. HU conversion models for
the pelvis were adopted from previous studies, further extended in this study also for head MRI
by generating anatomical site-specific conversion models (a new training data set of ten other brain
patients). This study also evaluated two other types of simplified sCT: dual bulk density (for bone and
water) and homogeneous (water only). For every clinical case, intensity modulated proton therapy
(IMPT) plans robustly optimized in standard planning CTs were calculated in sCT for evaluation,
and vice versa. Overall dose agreement was evaluated using dose–volume histogram parameters and
3D gamma criteria.
Results: In heterogeneous sCTs, the mean absolute errors in HUs were 34 (soft tissues: 13, bones:
92) and 42 (soft tissues: 9, bones: 97) in the head and in the pelvis, respectively. The maximum
absolute dose differences relative to CT in the brain tumor clinical target volume (CTV) were 1.4%
for heterogeneous sCT, 1.8% for dual bulk sCT, and 8.9% for homogenous sCT. The corresponding
maximum differences in the prostate CTV were 0.6%, 1.2%, and 3.6%, respectively. The percentages
of dose points in the head and pelvis passing 1% and 1 mm gamma index criteria were over 91%,
85%, and 38% with heterogeneous, dual bulk, and homogeneous sCTs, respectively. There were
no significant changes to gamma index pass rates for IMPT plans first optimized in CT and then
calculated in heterogeneous sCT versus IMPT plans first optimized in heterogeneous sCT and then
calculated on standard CT.
Conclusions: This study demonstrates that proton therapy dose calculations on heterogeneous sCTs
are in good agreement with plans generated with standard planning CT. An MRI-only based RTP
workflow is feasible in IMPT for brain tumors and prostate cancers. C 2016 American Association of
Physicists in Medicine. [http://dx.doi.org/10.1118/1.4958677]
Key words: MRI-only, radiotherapy treatment planning, substitute CT image, intensity modulated
proton therapy, Hounsfield unit conversion
1. INTRODUCTION
Magnetic resonance imaging (MRI)-based contouring is
presently standard practice in radiotherapy.1–4 Recently, the
use of MR images has been extended for the entire external
photon radiotherapy treatment planning workflow.5–18 The
development of techniques that construct electron density in
MRI-derived substitute computed tomography images (sCT,
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also known as pseudo CT, synthetic CT or virtual CT) has
been an essential milestone enabling omission of CT from
the workflow.5–7,9,10,12–16,19 Previous work in photon treatment
planning has shown that absorbed dose can be accurately
computed in sCT, and these images can also be applied
as reference images for image-guided radiotherapy (IGRT)
with x-ray-based localization.5–10,12,14,15,17,18 Clinical interest
in MRI localization-based IGRT has been growing in recent
years due to developments in MRI-guided radiotherapy, such
as MR-linacs, MR-on-rails, and table-trolley systems.20–24
Volumetric MR studies are also increasingly utilized for post-
treatment monitoring.25–27
High quality soft-tissue visualization in MRI assists target
delineationand imageguidanceneeded for intensitymodulated
proton therapy (IMPT) to realize its maximum clinical poten-
tial for avoiding radiation toxicity.28–31 Furthermore, an MRI-
only based planning process avoids MR-to-CT registration
uncertainties, minimizes radiation toxicity, and saves hospital
resources.5–10,12–16,18Online IMPTplanningon thebasis ofMR
localization imaging would be of major importance for MR-
proton radiotherapy systems that may appear in future.31,32
The feasibility of MRI-only based planning for particle
beam therapy has been tested previously by Edmund et al.14
and Rank et al.33,34Both works employed ultrashort echo time
(UTE) sequence-based sCT construction methods for the head
and reported approximately 2% dose calculation accuracy in
sCT compared to CT. Edmund et al. conducted dose calcula-
tions in several different types of sCT for uniformscanningpro-
tonbeamsinfivepatientswithsimulatedspherical tumor targets
placed between the nasal cavity and skull. In the best perform-
ing sCT, the mean absolute error (MAE) of Hounsfield units
(HUs) was 128. Rank et al. calculated proton and carbon ion
plans for three brain tumor cases using an in-house treatment
planning system.33,34 The MAE of HU in their case was 149.
Hartman et al. recently showed that a 0.6 T magnetic field
directed transverse to a proton beam during irradiation af-
fects the selection of IMPT spot positions due to Lorentz-force
deflectionof theprotons in air, but doesnot significantlydisturb
the dose distribution around the target.35 Field-induced deflec-
tion corrections are not relevant for oﬄineMRI, post-treatment
MRI, charged particles travelling parallel to amagnetic field,32
or if an MR-on-rails design is employed.23
In this paper,we focus specifically on evaluating dose calcu-
lationaccuracy for robustlyoptimized IMPTwithMRI-derived
planning sCTs for a validation cohort of ten brain tumor cases
and ten prostate cancer cases. Our work addresses dose uncer-
tainties in IMPT plans arising from three types of sCTs: (1)
homogeneous, (2) dual bulk, and (3) heterogeneous density
conversion.5–9,36 We compare the dose calculation accuracy
when performing robust IMPT plan optimization in the CT
followed by dose computation in sCT and vice versa.
2. METHODS
2.A. Construction of substitute CTs
The feasibility of MRI-only based planning with protons
was validated using 20 entirely different test cases (10 brain
tumors and 10 prostate patients) with three sCT generation
methods for use in IMPT: (1) assigning the entire body volume
to water-equivalent density (homogeneous), (2) setting an
average bulk density for bone and water-equivalent density
to the rest of the body (dual bulk), and (3) transforming
the voxel intensities of an in-phase MR image to HU by a
dual model conversion technique (heterogeneous). The latter
applies separate density conversion models for bone and soft
tissue after autocontouring bone outlines.5–7,9 The technique
has been used to generate heterogeneous sCTs of the pelvis,
and it is presently used in routine clinical external photon
MRI-only planning workflow for prostate cancer.4–7,9 In the
current study, this dual model HU conversion technique was
also extended to the head.
Imaging was performed according to our department’s
(Helsinki, Finland) standard procedures for MRI+CT-based
radiotherapy treatment planning (RTP) for both prostate and
brain tumor patients. Prostate patients undergoing MRI-only
based RTP protocol in our clinic were excluded from this
specific study because their simulation protocol does not
include CT scanning. Both MRI and CT simulations (MR
simulator: 1.5 T imager GE Optima MR450w, GE Medical
Systems, Inc., Waukesha, WI, USA. CT simulators: either
GE LightSpeed RT, GE Medical Systems, Inc., or Siemens
SOMATOM Definition AS, Siemens Healthcare, Erlangen,
Germany) were conducted with patient positioning similar
to that for treatment. The MR scanner was equipped with
accessories such as laser-localization system, flat table top,
MR compatible fixation devices, and receiver coil frames.6,9,11
In-phase MR images obtained by a T1/T2*-weighted 3D
fast RF-spoiled dual gradient echo sequence were used to
create sCT because previous work had shown that accurate
heterogeneous sCT of the pelvis are obtained.6–9,11,36 Our
department’s standard simulation procedures for RTP already
contains the above dual echo sequence among a set of MR
examinations used mainly for target delineation. The same
imaging protocol was retained for the current study. The
specific sequence parameters for in-phase images were as
follows: TE = 4.2 ms, TR = 6.8 ms, flip angle = 15◦, and
bandwidth = 90.9 kHz (pelvis) or 62.5 kHz (head) with
approximate scan times of 2 and 3 min for the head and pelvis,
respectively. The applied standard MRI sequence does not
permit differentiation of cortical bone and air cavities (where
UTE sequences are required).6,7,9,13,37 This differentiation is
not required if treatment fields do not pass through air cavities,
that would typically be the case with proton beam therapy
for brain tumors.38–40 The system-related geometrical uncer-
tainties in the applied MR images remain within 1 mm [field-
of-view (FOV): 24 cm] in the head and within 2 mm (FOV:
42 cm) in the pelvis.5,9,11 The susceptibility-induced shifts of
tissue boundaries remain within 1 mm (soft tissue-bone) and
2 mm (soft tissue-air, mean body outline error of 1.2 mm
in pelvis).9,11 Although the entire MRI simulation protocol
included other sequences, the other images were not used
in this study. The imaging time for all sequences in the
current simulation protocol was about 12 and 20 min for
the head and the pelvis, respectively. The voxel size used in
the MR and CT images was about 1 mm3.
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The heterogeneous sCTs for ten prostate cancer patients
were obtained by following the clinical MRI-only plann-
ing workflow, in which the bone contouring and density
conversion are integrated into a commercial image processing
software   v5.6 (MIM Software, Inc., Cleveland, OH,
USA).4–9 The heterogeneous sCTs for ten brain tumor patients
were achieved by further extending the conversion technique
to the head. The conversion models were adjusted particularly
for this body site by using volume-of-interest (VOI)-based
correspondence between theMR intensities and CTHUs from
imaging data of ten other patients in the same setup.5,6,9 In
total, 700 VOIs (2 mm diameter, 4 mm3, 70 VOIs/patient)
were placed in different soft tissues and bones in theMR image
of the head (such as white matter, gray matter, cerebrospinal
fluid, cortical bone, and spongy bone). The MR image was
rigidly coregistered to the CT using the mutual information
method in  , and the average HU and MR intensities
in each VOI were recorded as paired values.
The sampled-VOI data were used to create HU conversion
models separately within and outside of a bone segment. In
bone, the conversion model was an exponential fit to the data.
In soft tissue, the conversion model was a piecewise function
that segregates fluid, white matter, gray matter, and scalp
according to themean and standard deviation ofMR intensities
for particular tissue type. For each tissue type, an appropriate
average HUwas assigned.41–44 Potential gaps in theMR inten-
sity scale between tissues were bridged by linear interpolation.
The resulting conversion models were integrated into a
commercial medical image processing software ( ).
Conversion time from MR image to the sCT was approxi-
mately 30 s per patient with Intel Xeon quad-core (3.07 GHz)
processor accompanied by 12 GB of RAM. For validation,
the technique was applied for the ten different brain tumor
patients (precise manual bone contouring followed by the
autotransformation of MR intensities into HUs). The HU
accuracy in the resulting sCTs was analyzed by HU value
comparison against CT images using the same VOI-based
sampling as for generating the models.
2.B. Treatment planning
IMPT plans for ten prostate and ten brain treatments
were produced on a stand-alone PC using  v4.7.2
treatment planning software (Raysearch Laboratories, Stock-
holm, Sweden) and a generic scanned pencil beam model for
a compact single-gantry proton delivery system. Clinically
feasible plans were produced using a standard snout (10 cm)
and standard range shifters (0, 4.5, and 7 cm). Minimum spot
weights were fixed at 0.01 monitor units per fraction, but
there were no explicit restrictions for spot arrangement or
number of energy layers. Couch rotation in each plan was
fixed at 0◦. Treatment plan isocenters for brain treatments
were placed at the midsagittal plane and on the transverse slice
containing the center of mass of the planning target volume
(PTV); however, the anterior–posterior (AP) placement was
individually adapted in each plan. Treatment plan isocenters
for prostate treatments were always located at the center of
mass of the clinical target volume (CTV).
Dose to theCTVwas inverse-plannedwith robust optimiza-
tion with respect to localization perturbation and range uncer-
tainty.45Surrounding dose fall-off andmaximumdose–volume
histogram (DVH) objective functions were used to minimize
dose outside the CTV. Each plan was first optimized and
computed on CT, and then only dose was computed in each
type of sCT. This validated the accuracy of dose calculation
in an sCT relative to the CT. To examine the effect of sCT
on plan optimization, we made fresh optimizations first in
each sCT and then computed dose only in the CT. Only for
the purpose of accurately testing dose discrepancies within
the body arising mainly due to sCT density assignment, we
removed the effect of patient misalignment between CT and
MRI scans by using an identical external skin outline in both
sCT and CT. The skin outline in the CT was copied to the
MRI, but only tissue voxels in the MRI overlapping with the
CT were used to generate the sCT.3,5,9 Possible complement
volume between CT and MRI skin contours (CT\MRI) was
set to water equivalent. In an MRI-only clinical workflow, this
step is not required since the sCT conversion will involve the
entire patient outline found in the MRI scan.
For robust optimization using the worst-case method,45 we
applied spatial offsets of 1, 2, and 3 mm in each cardinal
direction, due to uncertainties from beam modeling, organ
delineation and residual errors in patient localization. Beam
range uncertaintywas simulated in the robustness optimization
by uniformly scaling all physical density values up and down
by 3%, with and without the spatial perturbation.
A template-based approach was used for prostate plans
with bilateral beams at constant gantry angles of 90◦ and
270◦, and no range shifter. Final dose was calculated on a
2 mm isotropic grid and rescaled such that 2.2 Gy [relative
biological effectiveness (RBE)] dose per fraction was always
prescribed to 98% of PTV.
A wide range of tumor volumes and locations required
an individually customised approach for brain IMPT beam
placement. One or two beams were positioned to avoid the
eyes, brainstem, and air cavities. The plans sampled a wide
variety of different gantry angles, range shifters, and isocenter
placements. Final dose was calculated on a 1 mm isotropic
grid and rescaled for 2.2 Gy (RBE) per fraction prescribed to
95% of CTV.
For planned and evaluation dose analysis, the entire dose
grid covering all targets and organs at risk was extracted
with  scripting for gamma analysis. Gamma index
“pass” rates were calculated over dose grid points in sCT
with 10% of the prescribed dose or higher, for several dose
and distance criteria, compared to the dose calculated in CT.
DVH statistics were obtained from the plan printouts. For
wider generalizability, we also compared CT versus sCT dose
calculation accuracy in IMPT to volumetric modulated arc
therapy (VMAT) using 6 MV photons.
3. RESULTS
3.A. Heterogeneous substitute CTs
Table I shows the HU conversion models used in the head
scans to transform in-phase MR images into sCTs. Figures 1
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T I. The dual conversion models for the head to transform in-phase MR
image intensity values into HUs separately for bone and soft tissue.
Tissue
type MR intensity (x) HU Details
Bone x < 200 1441 Cortical bone
200 ≤ x ≤ 2000 e7.42−0.001x+1.3×10
−7
x
2
Mixed bone tissues
x > 2000 360 Spongy bone
Soft tissue x < 338 12 Fluid
338 ≤ x < 576 From 12 to 45a Boundaries and noise
576 ≤ x < 798 45 Gray matter
798 ≤ x < 1060 25 White matter
1060 ≤ x < 2285 From 25 to −83a Boundaries and noise
x > 2285 −83 Scalp
aThe MR intensities were transformed into HUs with linear interpolation.
and 2 illustrate examples of heterogeneous sCTs of the head
and the pelvis, respectively, shownwith display window levels
for soft tissue and bone. All heterogeneous sCTs reliably
reproduced the qualitative appearance of different tissue types
found in the head and pelvis as in CT. The overall HU MAE
in heterogeneous head sCTs was 34 HU (13 HU in soft tissue,
92 HU in bone). These uncertainties were comparable to the
overall MAE in heterogeneous pelvic sCTs of 42 HU (9 HU
in soft tissue, 97 HU in bone).
3.B. Dose calculation accuracy in substitute CTs
The distributions of DVH differences between sCTs and
CTs were summarized in box-and-whisker plots for the ten
brain cases (Fig. 3, omitting the homogeneous sCT) and for
the ten prostate cases (Fig. 4). The relative cumulative volume
of a target or risk organ has been plotted on the horizontal
axis, and the percentage dose difference in sCT relative to
CT has been plotted on the vertical axis. The mean CTV
dose differences between heterogeneous sCTs and CTs were
−0.2% (range: −1.4%–0.9%) and 0.1% (range: −0.5%–0.6%)
for the ten brain tumor and ten prostate cancer patients,
respectively. The corresponding dose differences in dual bulk
sCTs were 0.1% (range: −1.4%–1.8%) and −0.3% (range:
−1.2%–0.8%), respectively. Larger CTV dose differences
were observed for homogenous sCT both in head (mean:
−1.6%, range: −8.9%–2.3%) and in pelvis (mean: 0.7%,
range: −3.6%–2.4%).
Forwhole brainDVHs [Fig. 3(B)], themean difference (and
range) in calculated dose from CTwas −0.1% (−1.1%–2.6%),
0.1% (−1.2%–0.7%), and 1.5% (−2.8%–13.8%) for heteroge-
neous, dual bulk, and homogeneous sCTs, respectively. In
rectal DVHs, mean sCT differences were within 0.1% of CT
and worst differences were within 1.8% in all cases. In bladder
DVHs, heterogeneous sCTs performedwell in all cases (mean:
0.0%, range: −0.4%–0.9%), but there were differences up to
3% in dual bulk sCT (mean: −0.4%, range: −3.1% to 0.8)
and up to 10% in homogeneous sCT (mean: 0.3%, range:
−2.2%–10.2%).
Table II presents the gamma index evaluations for IMPT
plans between CT and sCT for every dose point over 10%
F. 1. An example of a heterogeneous sCT of the head in (A) displayed with
soft tissue window (left) and bone window (right). The original MR in-phase
image is shown in (B) on the left and the standard planning CT in (B) on the
right.
of the prescribed dose. With the heterogeneous sCTs of both
pelvis and brain, the mean pass rate for the 1% and 1 mm
gamma index criterion was over 95% (worst cases: 92.4% in
pelvis and 90.5% in head). Dual bulk sCTs hadmean pass rates
over 95% for the 2% and 2 mm criterion. The homogeneous
sCT did not reach average pass rates over 95% even with 3%
and 3 mm gamma index criterion.
A further consideration for IMPT planning is whether the
use of a sCT during robust optimization has any effect on
dose calculation accuracy relative to CT. Ideally, the dose
calculation accuracy should remain the same with respect
to interchanging the image sets used for inverse-planning
and dose calculation. Figure 5 presents the gamma index for
each plan created using a sCT and then evaluated for dose
calculation in CT, plotted as a function of its corresponding
CT-planned and sCT-evaluated gamma index.
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F. 2. An example of a heterogeneous sCT of the pelvis in (A) displayed
with soft tissue window (left) and bone window (right). The original in-phase
MR image is shown in (B) on the left and the standard planning CT in (B) on
the right.
The photon dose calculation results followed roughly the
same pattern of agreement as with protons. Mean prostate
PTV dose differences in calculated VMAT photon plans
between sCTs and CTs were −0.1% (range: −0.5%–0.3%),
0.4% (range: −0.4%–1.0%) and −1.2% (range: −2.2%–0%)
for heterogeneous, dual bulk, and homogeneous sCTs, respec-
tively. The corresponding evaluations for brain PTV dose
differences were −0.1% (range: −0.4%–0.7%), 0.3% (range:
−0.1%–0.9%), and −2.7% (range: −3.9 to −1.0).
4. DISCUSSION
The current standard for proton treatment planning is
the dose distribution calculated on a CT obtained during
simulation. We herein show that it is feasible to calculate
proton dose on sCT derived solely from MR images, such
that a given planned distribution of spots (and spot weights)
yields dose distributions that are in close agreement to those
in CT image sets. The dose calculations in different type
of sCTs illustrate the influence of heterogeneity to the dose
agreement. For targets in the head and pelvis, dose differences
from heterogeneous sCT to CTweremainlywithin 0.5%.Also
gamma indices were satisfactory for both targets and healthy
tissues, even for 1% and 1 mm criteria. The dose calculation
uncertainty due to heterogeneous sCT construction is therefore
comparable or minor in magnitude to potential uncertainties
caused by CT-to-density calibration uncertainties, anatomical
changes in the patient, and IGRT localization errors.46–48
F. 3. Differences in dose (reference planning data was actual CT, then
IMPT doses were calculated in heterogeneous and dual bulk sCTs) at a given
cumulative relative volume for the (A) CTV and (B) whole brain. The dashed
lines indicate the ±1% relative dose difference in sCT compared to dose
calculated in actual CT. The results for CTV and whole brain DVHs in the
homogeneous sCTwere ranging up to 8.9% and to 13.8%, respectively. These
have been omitted from the figure to preserve visual clarity.
In addition to heterogeneous tissue presentation, the dual
bulk sCTs performed well reaching IMPT dose calculation
accuracy better than 2% for all cases. The fully homogeneous
sCTs introduced unacceptable dose errors for some patients.
Hence, the use of sCTs including at least separate bulk
densities for bones and soft tissues is essential, while increas-
ing heterogeneity further provides higher dose accuracy and
reliability for all patients. With heterogeneous and dual bulk
sCTs, the proton dose calculation uncertainty was nearly in
a comparable level with external photon MRI-only based
planning.
The good performance of dual bulk sCTmay have stemmed
from the selected beam directions. The beams had been
directed mostly through bones having relatively homogeneous
composition (e.g., femoral heads and skull). If beams pass
through bones with a dense shell of cortical bone covering
less-dense bone marrow (e.g., femur, ilium, and pubic bone),
then the heterogeneous tissue presentation in sCTs appears to
be essential for accurate dose calculation.36 In head and neck
cases, where the treatment beams must be directed through air
cavities, an accurate heterogeneous sCTswould bemandatory.
If the tumor is located in a close proximity to nasal cavities
or when applying beams from the anterior direction, accurate
representation of bone structure, cartilage, and air cavities is
essential. In such cases, a clinical user should use either UTE
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F. 4. Differences in dose (reference planning data was actual CT, then
IMPT doses were calculated in heterogeneous and dual bulk sCTs) at a given
cumulative relative volume for the (A) prostate CTV, (B) rectum, and (C)
bladder. Dashed lines indicate the ±1% relative dose difference compared to
dose calculated in actual CT.
sequence-based or atlas-based approaches for sCT generation.
However, accurate representation of air-bone interfaces could
be challenging even with those sCT construction methods that
might be a reason for higher HU uncertainty for the head in
previous studies (MAE: 126–149) compared to the present
work excluding air cavity volumes (MAE: 34).13,14,19,33 In
the conversion-based heterogeneous sCTs of the pelvis, the
HU MAE was similar (whole pelvis: 42, bones only: 97) to
that reported previously (whole pelvis: 37–74, only bones:
98–134).5,9,12,49,50 Earlier studies have shown that various
types of heterogeneous pelvic sCTs perform dosimetrically
acceptably for dose calculation with photons. According to
the current study, heterogeneous sCTs are also acceptable for
IMPT planning.12–14,17,49,50
The heterogeneous sCT generation method used in the
current study relies on bone segmentation of the MR image,
before performing the distinct MR intensity to HU conversion
within and outside of the segment. Our method was designed
to be highly accessible and easily adopted by most clinical
users, but the method commissioning has some limitations.
Every user needs to commission and validate a suitable bone
segmentation algorithm. Due to the straightforward direct
conversion process, conversion models should be revalidated
in case of any changes in the MR platform or acquisition that
leads to changes in MR absolute intensities or in the image
uniformity.5,9,11 The method is robust for general changes in
MR intensity levels and in the absence of major artifacts.
Intrafraction uncertainties would still need to be accounted
for using adequate margins or adopting a target motion-
following approach. The latter is an appealing future appli-
cation of MR-guidance during beam delivery. With this
conversion method it is possible to generate an sCT rapidly
(within 30 s) but the time required for autosegmentation
and treatment plan optimization remain the limiting steps.
However, our method would be readily compatible with future
advances in online adaptive replanning that could address
some of these computational issues.
Although a large number of details could be examined
in regards to plan quality, this study design focused only
on the potential dose calculation errors arising due to use
of sCT, relative to CT-simulation. Our beam arrangements
in the head were designed to avoid treatment through air
cavities. In prostate cases, air pockets in the lower bowel
were occasionally unavoidable. The sCT generation methods
above had assigned bowel gas as water-equivalent.6 This led
to an additional contribution to the observed dose differences
in the prostate plans. The use of a matching skin contour
between sCT and CT, as we have described above, was
considered as the best solution to avoid dose comparison
T II. The percentages of dose points of IMPT plans in sCTs compared to those in CTs that passed the 3D
gamma index criteria are presented as averages (and range) of ten patients each in the pelvis and in the head.
3D gamma index criteria
3% & 3 mm 2% & 2 mm 1% & 1 mm
Pelvis
Heterogeneous 99.6 (99.0–100) 98.6 (97.2–99.9) 95.0 (92.4–98.2)
Dual bulk 98.8 (97.2–99.8) 97.2 (95.0–99.4) 92.6 (89.6–95.8)
Homogeneous 90.7 (87.5–94.5) 86.8 (83.0–91.0) 78.7 (74.0–83.8)
Head
Heterogeneous 99.9 (99.8–100) 99.5 (98.0–100) 95.9 (90.5–100)
Dual bulk 99.9 (99.1–100) 99.3 (96.6–100) 94.3 (85.1–99.9)
Homogeneous 84.1 (76.0–98.2) 71.5 (57.9–80.4) 53.6 (38.4–63.2)
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F. 5. The effect on dose calculation agreement due to the image type used
for inverse planning is shown for IMPT plans in the (A) head and (B) pelvis.
The horizontal axis gives gamma indices for plans created using CT and then
evaluated for dose calculation accuracy in different types of sCT. The vertical
axis gives corresponding gamma indices for plans created with an sCT then
evaluated in the CT. The locus of points which are invariant with respect to
interchanging image sets are plotted as a dashed line as an aid for the eye.
uncertainties stemming from patient body outline changes
observed between MR and CT scans. Automated deformable
registration was considered as an option to avoid the need
for manual correction of the skin contour, but that would
have introduced additional registration-related uncertainties
for internal organs. With manual correction of the air-skin
interface, it was mainly the internal changes of organs (e.g.,
rectal gas) between CT and MR simulation that would have
contributed to the dose differences in addition to the intrinsic
quality of sCT construction. The change in bladder filling was
minimal as scans were acquired one following the other as a
part of the routine clinical RTP simulation workflow.
Robustness is presently considered a standard requirement
for proton therapy planning, so we have incorporated robust
optimization in all of our IMPT plans.51–55 Our robustness
settings assume that any systematic and random shift in
the target position will be accounted for using daily online
imaging and position correction; this would be reasonable
for proton therapy given recent developments in IGRT.56–58
Robustness settings would have no impact on the average
dose agreement between heterogeneous sCT andCT. Different
perturbation distances might shift the observed gamma pass
rates for homogeneous sCT and dual bulk sCT relative to the
(dotted) line of equivalence on Fig. 5.
Some studies have pointed out uncertainties in the stopping
power ratios for protons used in the dose computation.59–61Our
findings remain unchanged because our dose calculations used
a fixed relationship between physical density and stopping
powers for all image sets.We have used 3% scaling of physical
density in robust optimization to allow for potential errors in
the stopping power ratios.During robust optimization, the dose
calculation accuracy relative toCTwas unaffected by using the
heterogeneous sCT, and only minimally using the dual bulk
sCT. Fully homogeneous sCT performed poorly for accuracy
relative to CT when used for the optimization. In Fig. 5(A),
with homogeneous sCT there is a general tendency for the
points to lie above and to the left of the line of invariance. In
Fig. 5(B), the tendency instead is for the points to lie below
and to the right of the dashed line. In the head, there is a
relatively little density variation within brain tissue, and the
cranium is approximately a uniform spherical shell of cortical
bone overshadowing the target volume. Plans optimized first
in the sCT are less sensitive to internal density variations
but are affected by patient shape, and hence return higher
gamma pass rates compared to plans optimized first in the CT.
In the pelvis, the bones are irregular in shape and provide
differential shielding of the target when viewed along the
beam axis. The bone density structure is also more complex,
being a composite of bone marrow, spongy bone and cortical
bone. Plans optimized first in the homogeneous sCT do not
adequately account for changes in both shape and physical
density, and hence can return lower pass rates compared to
plans optimized first in the CT. We propose that the effect
of using sCT in different robust optimization approaches
would be an interesting subject for further study. The body
of published work on MRI-only based treatment planning for
proton therapy suggests that this is a promising area of future
clinical utility; therefore, further publications on this subject
would be warranted for pediatric proton therapy or address
treatment sites other than brain and prostate.
5. CONCLUSIONS
This study shows that proton dose calculation can be per-
formed accurately inMRI-derived sCT images for brain tumor
and prostate cancer cases. Overall, proton dose computation
in sCT images was marginally more accurate in prostate
plans than for brain plans. Heterogeneous sCTs achieved dose
agreement of approximately 1% or better for target volumes
and organs at risk for all patients both in head and pelvis
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regions. Dose agreement comparedwith CTwas unaffected by
robust optimization when using the heterogeneous sCT as the
planning image set. Robust optimization can also be reliably
performed in heterogeneous sCTs wherein the patient’s shape
and density variations have been reproduced with high
fidelity. Dual bulk sCTs also attained 1% level of dose
agreement for many patients, but showed larger variability
in dose uncertainties regarding the entire patient groups, and
included also higher risk for dose errors in small volumes
of targets and healthy organs. However, the dose accuracy
remained sufficient, and thus the dual bulk sCTs could also be
considered for clinical applications if heterogeneous sCTs are
unavailable. Fully homogenous density substitution cannot be
recommended in any case.
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